Suppressed Bone Turnover by Long‐Term Bisphosphonate Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of Dog Rib

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Bone and Mineral Research

• Publication date

  2004-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1359/JBMR.040126PMID 15125797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐Term Treatment of Incadronate Disodium Accumulates Microdamage but Improves the Trabecular Bone Microarchitecture in Dog Vertebra

  2003influential reference
• Bone Histomorphometric and Biochemical Marker Results of a 2‐Year Placebo‐Controlled Trial of Raloxifene in Postmenopausal Women

  2002cited by this paper
• Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles.

  2001cited by this paper
• Long‐Term Effects of Withdrawal of Bisphosphonate Incadronate Disodium (YM175) on Bone Mineral Density, Mass, Structure, and Turnover in the Lumbar Vertebrae of Ovariectomized Rats

  2001cited by this paper
• Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?

  2000cited by this paper
• The Histological Appearance of Stress Fractures

  2000cited by this paper
• Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib

  2000influential reference
• Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

  2000cited by this paper
• Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

  2000cited by this paper
• Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

  1999cited by this paper
• A brief review for orthopedic surgeons: Fatigue damage (microdamage) in bone (its determinants and clinical implications)

  1998cited by this paper
• Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

  1998cited by this paper
• Preadministration of incadronate disodium can prevent bone loss in rat proximal tibial metaphysis when induced by hindlimb immobilization by bandage.

  1998cited by this paper
• Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures.

  1997cited by this paper
• Bisphosphonates: preclinical aspects and use in osteoporosis.

  1997cited by this paper
• Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

  1997cited by this paper
• Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

  1997cited by this paper
• Bone Microdamage and Skeletal Fragility in Osteoporotic and Stress Fractures

  1997cited by this paper
• Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

  1997cited by this paper
• In vivo trabecular microcracks in human vertebral bone.

  1996cited by this paper
• Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

  1996cited by this paper
• Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs.

  1995cited by this paper
• Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction

  1995cited by this paper
• Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo.

  1995cited by this paper
• Basic biomechanical measurements of bone: a tutorial.

  1993cited by this paper
• Determination of a new bisphosphonate, YM175, in plasma, urine and bone by high-performance liquid chromatography with electrochemical detection.

  1992cited by this paper
• Frequency distributions of tetracycline‐based measurements: Implications for the interpretation of bone formation indices in the absence of double‐labeled surfaces

  1990cited by this paper
• Validity of the bulk-staining technique to separate artifactual from in vivo bone microdamage.

  1990cited by this paper
• Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

  1987cited by this paper
• Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee

  1987cited by this paper

• Long-term bisphosphonate use and femoral morphological changes in osteoporosis patients: a retrospective cohort study

  2025cites this paper
• Romosozumab Following Long-Term Bisphosphonate Use for Severe Osteoporotic Vertebral Collapse (Vertebra Plana): Potential Facilitation of Vertebral Fracture Healing

  2025cites this paper
• Evaluation of cortical bone remodeling in canines treated with daily and weekly administrations of teriparatide by establishing AI-driven morphometric analyses and GIS-based spatial mapping

  2023cites this paper
• Trabecular bone microcrack accumulation in patients treated with bisphosphonates for durations up to 16 years

  2022cites this paper
• Biomechanical mechanisms of atypical femoral fracture.

  2021cites this paper
• The nature of osteoporosis

  2021cites this paper
• On the evolution and contemporary roles of bone remodeling

  2021cites this paper
• Effects of anti-resorptive treatment on the material properties of individual canine trabeculae in cyclic tensile tests.

  2021cites this paper
• Comparison of the Efficacy and Renal Safety of Bisphosphonate Between Low-Dose/High-Frequency and High-Dose/Low-Frequency Regimens in a Late-Stage Chronic Kidney Disease Rat Model

  2020cites this paper
• Osteoporosis Treatments Affect Bone Matrix Maturation in a Rat Model of Induced Cortical Remodeling

  2020cites this paper
• Fifty years of bisphosphonates: What are their mechanical effects on bone?

  2020cites this paper
• Impaired bone quality characterized by apatite orientation under stress shielding following fixing of a fracture of the radius with a 3D printed Ti-6Al-4V custom-made bone plate in dogs

  2020cites this paper
• Persistent Activation of Calcium‐Sensing Receptor Suppresses Bone Turnover, Increases Microcracks, and Decreases Bone Strength

  2019influential citation
• Minodronate for the treatment of osteoporosis

  2018cites this paper
• Evaluation of bone turnover after bisphosphonate withdrawal and its influence on implant osseointegration: an in vivo study in rats

  2018cites this paper
• Material heterogeneity, microstructure, and microcracks demonstrate differential influence on crack initiation and propagation in cortical bone

  2018cites this paper
• Low Dose of Bisphosphonate Enhances Sclerostin Antibody‐Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model

  2018cites this paper
• Accumulation of microdamage at complete and incomplete fracture sites in a patient with bilateral atypical femoral fractures on glucocorticoid and bisphosphonate therapy

  2018cites this paper
• The effects of rhBMP-2 on bone healing in ovariectomized rats treated with zoledronic acid and dexamethasone

  2018cites this paper
• Interaction of Microcracks and Tissue Compositional Heterogeneity in Determining Fracture Resistance of Human Cortical Bone.

  2018cites this paper
• Zoledronic Acid Induces Site-Specific Structural Changes and Decreases Vascular Area in the Alveolar Bone.

  2018cites this paper
• Effects of suppressed bone remodeling by minodronic acid and alendronate on bone mass, microdamage accumulation, collagen crosslinks and bone mechanical properties in the lumbar vertebra of ovariectomized cynomolgus monkeys.

  2017cites this paper
• Bisphosphonates and atypical subtrochanteric fractures of the femur

  2017cites this paper
• Atypical femoral fractures related to bisphosphonate treatment: ISSUES AND CONTROVERSIES RELATED TO THEIR SURGICAL MANAGEMENT

  2017cites this paper
• Atypische Femurfraktur bei liegender Hüfttotalendoprothese unter langjähriger Bisphophonat-Therapie

  2017cites this paper
• Bone Biomechanics and Bone Quality: Effects of Pharmaceutical Agents Used to Treat Osteoporosis

  2016cites this paper
• Local pamidronate influences fracture healing in a rodent femur fracture model: an experimental study

  2016cites this paper
• Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw

  2016cites this paper
• Elucidating Vacuolar H+-ATPase Subunit Interactions: A Systematic Structural Analysis

  2015cites this paper
• Questioning the association between bisphosphonates and atypical femoral fractures

  2015cites this paper
• Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures

  2015cites this paper
• Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs.

  2015cites this paper
• Spontaneous Bilateral Femoral Fractures After High-Dose Zoledronic Acid.

  2015cites this paper
• The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate.

  2014cites this paper
• Biomechanics of spinal metastases

  2014cites this paper
• Images in medicine - bisphosphonate induced atypical fracture.

  2014cites this paper
• Femoral Shaft Cortical Pathology associated with longterm Alendronate Therapy: A New Classification

  2013cites this paper
• Atypical femoral fractures.

  2013cites this paper
• Microdamage: Its Role in the Mechanical Integrity of Low Bone Mass Diseases and its Treatment Implications

  2013influential citation
• Burden of bisphosphonate‐associated femoral fractures

  2013cites this paper
• Bisphosphonate therapy and atypical fractures.

  2013cites this paper
• Mineralization- and remodeling-unrelated improvement of the post-yield properties of rat cortical bone by high doses of olpadronate.

  2013cites this paper
• Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta

  2013cites this paper
• Biochemical Bone Markers as Predictors of Excessive Bone Turnover Suppression during Osteoporosis Treatment with Bisphosphonates

  2013cites this paper
• In vivo microdamage is an indicator of susceptibility to initiation and propagation of microdamage in human femoral trabecular bone.

  2013cites this paper
• The relative influence of damage versus density on trabecular bone mechanical behavior

  2012cites this paper
• Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta.

  2012cites this paper
• Oral health and bisphopshonate-associated jaw osteonecrosis

  2012cites this paper
• FINITE ELEMENT ANALYSIS OF CANCELLOUS BONE

  2012cites this paper
• Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report

  2012cites this paper
• What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.

  2012cites this paper
• The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing

  2011cites this paper
• Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis

  2011cites this paper
• Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know.

  2011cites this paper
• Denosumab and bisphosphonates: different mechanisms of action and effects.

  2011cites this paper
• Femoral shaft fractures in the elderly--role of prior bisphosphonate therapy.

  2011cites this paper
• Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects.

  2011cites this paper
• Why bones bend but don't break.

  2011cites this paper
• Use of bisphosphonates in the management of postmenopausal osteoporosis

  2011cites this paper
• A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid

  2011cites this paper
• Measures of bone quality and their relationship to bone mechanical properties

  2011cites this paper
• Alendronate treatment elicits a reduction in fatigue-life of canine cortical bone

  2011cites this paper
• Successful treatment of advanced bisphosphonate‐related osteonecrosis of the mandible with adjunctive teriparatide therapy

  2011cites this paper
• Is Surgery Necessary for Femoral Insufficiency Fractures after Long-term Bisphosphonate Therapy?

  2010cites this paper
• A rational approach to management of alendronate-related subtrochanteric fractures.

  2010cites this paper
• Angiogenesis/osteogenesis in bisphosphonate-related osteonecrosis of the jaw: In vitro assessment in co-cultures of human endothelial and osteoblastic cells

  2010cites this paper
• EFEITOS DA Calcarea phosphorica 6CH E DO ALENDRONATO NA REPARAÇÃO DE LESÃO ÓSSEA EM

  2010cites this paper
• Mechanical Properties : What we think we know and what we know that we don ’ t know

  2010influential citation
• Femoral Insufficiency Fractures Associated with Prolonged Bisphosphonate Therapy

  2010cites this paper
• Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.

  2010cites this paper
• The Development and Validation of a Finite Element Model of a Canine Rib For Use With a Bone Remodeling Algorithm.

  2010cites this paper
• Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate

  2009cites this paper
• Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk

  2009influential citation
• Studying the role of microcracks in the pathophysiology of BRONJ

  2009cites this paper
• Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review.

  2009cites this paper
• COMPUTATIONAL MODEL OF ALENDRONATE EFFECTS ON CANINE RIB REMODELING AND MICRODAMAGE

  2009cites this paper
• Analysis of bone activity of jaws using scintigraphy on patients before, during and after treatment with IV bisphosphonates: A retrospective study

  2009cites this paper
• Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

  2009cites this paper
• COMPUTATIONAL MODEL OF ALENDRONATE EFFECTS ON CANINE RIB REMODELING AND MICRODAMAGE

  2009cites this paper
• Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene

  2009cites this paper
• THe effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib

  2009cites this paper
• Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.

  2009cites this paper
• Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws.

  2009cites this paper
• Low Bone Turnover and Microdamage? How and Where to Assess It?

  2008cites this paper
• Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study.

  2008cites this paper
• New developments surrounding the safety of bisphosphonates

  2008cites this paper
• Alendronate Reduces Bone Toughness of Ribs without Significantly Increasing Microdamage Accumulation in Dogs Following 3 Years of Daily Treatment

  2008influential citation
• Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs

  2008influential citation
• The Influence of Local Bisphosphonate Treatment on Implant Fixation

  2008cites this paper
• Surface-specific Bone Formation Effects of Osteoporosis Pharmacological Treatments

  2008cites this paper
• Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment

  2008cites this paper
• Skeletal Microdamage: Less About Biomechanics and More About Remodeling

  2008cites this paper
• CHAPTER 2 – The Nature of Osteoporosis

  2008cites this paper
• Die Bisphosphonat-assoziierte Osteonekrose der Kiefer Leitlinien zur Diagnostik, Therapie und Prävention der BON in der zahnärztlichen Praxis Schlüsselwörter: Osteoporose, Skelettmetastasen, Risikofaktoren, Therapieresistenz, Prävention

  2008cites this paper
• Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment.

  2008cites this paper
• Chapter 81 – Bisphosphonates: Mechanisms of Action

  2008cites this paper
• "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.

  2008cites this paper
• Low Bone Turnover and Microdamage? How and Where to Assess It?

  2008cites this paper
• Osteonecrosis of the jaws and bisphosphonates

  2008cites this paper
• Mineralization, microdamage, and matrix: How bisphosphonates influence material properties of bone

  2007influential citation